Subscribe now
Previous episodes
John Kitchens, MD, and Scott Krzywonos ask Thomas Stone, MD, what the 2026 midterms could mean for retina practices, from drug pricing and surgical reimbursement to biosimilars. Then Ehsan Rahimy, MD, joins to explain how the PRIMA subretinal implant works for advanced geographic atrophy, what three years of PRIMAvera data show, and why FDA action may come by early 2027.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Business of Retina After the Midterms (Thomas Stone, MD)
Scott floats a thesis that 2026 echoes 2006, and that the healthcare reform of 2008 could occur again in 2028 if a Democrat takes the White House. John and Tom expect little legislative change before 2029 because of the presidential veto, but see the results giving Democrats a platform on healthcare.
Tom’s watch list: continued pressure on surgical reimbursement. Expansion of Inflation Reduction Act drug negotiation, with 20 more drugs selected in 2027 and talk of 50. Proposals to shorten the biologic timeline from 11 years to 5. Medicare expansion options, including a public option and a lower eligibility age.
GLOBE Project: Tom says it is not high on his radar. John expects the impact to fall on manufacturers and distributors more than on practice drug reimbursement.
2027 practice economics: biosimilars have created a market practices must respond to. Tom points to Lucentis, where ASP erosion left practices underwater.
Patient assistance: after two years of uncertainty in Medicare Advantage copay foundation funding, a fund covering several hundred of Tom’s patients sunset in October. Practices need to be ready to enroll patients the moment funds open.
Meetings: Tom previews the Cencora Vision Exchange in Orlando and the March 2027 Business of Retina meeting, which will feature a keynote speaker from Microsoft covering AI, as well as sessions on staffing and recruitment.
Vitreoretinal View: PRIMA Implant (Ehsan Rahimy, MD)
The device: a 2 x 2 mm, 30 µm photovoltaic chip with 378 pixels, placed subretinally with no battery or cables. Glasses with a camera and pocket processor project near infrared light onto the chip, which stimulates bipolar cells. Patients combine form vision with native peripheral vision.
The surgery: pars plana vitrectomy, subretinal bleb, roughly 3 mm retinotomy, a pick to separate adherent retina at the GA border, and perfluorocarbon to stabilize the chip on insertion. Tamponade is required (70% gas, 30% oil in PRIMAvera). No retinotomy laser.
Rehabilitation: more than 60 hours of structured training. Dr. Rahimy expects US centers of excellence.
Outcomes: ~25 ETDRS letters gained at 12 months and about 30 at 36 months. 84% of compliant participants reported reading letters and words, and 52% used the device for complex tasks such as playing cards. Entry acuity was no better than 20/320 in the study eye and 20/200 in the fellow eye.
Safety: 38 patients, 17 sites, five countries. 27 completed 36 months. Seven died of all-cause mortality, none attributed to the device or procedure. 29 serious adverse events, 83% within 6 months. Natural vision was preserved. Placement in maculas 50 µm or thinner is best avoided.
Compared to Argus II: Argus is epiretinal and RF powered, with about 60 electrodes and extraocular cables. PRIMA is subretinal, uses 378 pixels at 100 µm pitch, and did not migrate beyond GA borders.
FDA: two Humanitarian Use Device designations, for advanced GA and Stargardt disease. Dr. Rahimy says Science Corporation has filed for a Humanitarian Device Exemption, with a decision possible by year end or early 2027. Candidates need pure GA with intact inner retina, so concurrent glaucoma would exclude a patient.
Key Takeaways
The hosts see little chance of healthcare legislation before 2029, but drug pricing and reimbursement debates could reach retina sooner.
The market, more than politics, is driving 2027 practice economics: biosimilars, ASP erosion, and shifting patient assistance funds.
PRIMAvera showed functional central vision gains in end-stage GA with a manageable safety profile, and a US decision could come within months.
Candidates are narrow: advanced GA, intact inner retina, and capacity for extensive rehabilitation.
Sponsors
This episode of RetinUp is supported by Genentech, Astellas, and Alcon.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
RetinUp turns one year old. John Kitchens, MD, and Scott Krzywonos look at the past 18 months of major retina acquisitions, including Merck/EyeBio, Lilly/Adverum, Biogen/Apellis, and AbbVie/Regenxbio, and what may come next. Donald J. D’Amico, MD, then goes deep on the BRUNELLO trial data. Producers Laura Brown and Liz Hogan join the hosts to look back on the first year.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
Big Pharma Comes to Retina
Four major deals in eighteen months: Merck/EyeBio (up to $3B, 2024), Eli Lilly/Adverum Biotechnologies (up to $262M, 2025), Biogen/Apellis ($5.6B, 2026), AbbVie/Regenxbio licensing partnership (up to $1.75B). Only Apellis had an approved drug at time of acquisition.
The gold rush is not over. Kodiak Sciences, with a multi-indication BLA in Q4 2026, is a prime target. EyeBio founders David R. Guyer, MD, and Tony Adamis, MD, co-founders of Eyetech and the first approved anti-VEGF, are now at Merck with remigromig and tiespectus in the pipeline.
BRUNELLO Deep Dive with Donald J. D'Amico, MD
Study recap: remigromig 0.5 mg and 0.8 mg monthly vs. ranibizumab 0.5 mg in DME. 25% were previously treated, and both doses met non-inferiority on BCVA change at week 52.
The Wnt pathway: remigromig activates FZD4 and two LRP5 epitopes simultaneously via a tetravalent, trispecific antibody that mimics norrin, the natural Wnt agonist in retinal vasculature. The pathway has stymied pharmacologists for decades.
The PDR signal: 6.1-6.7% in remigromig arms vs. 0.9% with ranibizumab. The signal is permissive, not causative. RISE/RIDE sham controls showed 16.3% PDR at year one, and VIVID/VISTA showed 11.1% at year two. Remigromig patients compare favorably to natural history.
Why ranibizumab 0.5 mg: the only active comparator with an established non-inferiority margin and a primarily monthly dosing label. The 0.5 mg dose reflects international standard, and the trial targets global approval.
Duration unknown: remigromig was dosed monthly in BRUNELLO, but effect duration is unstudied. Dr. D'Amico raises the possibility of three loading doses producing months of benefit. Combination with anti-VEGF is the logical next step. BAROLO companion study expected Q1-Q2 2027.
RetinUp Year One
Laura Brown: came in knowing nothing about retina and hopes to record live at a future meeting (specifically, Hawaii).
Liz Hogan: surprised by industry partners' warmth, and notes breaking news episodes turned around in under 12 hours are an industry best.
John Kitchens, MD: proud of editorial independence and breaking news speed, and wants weekly episodes and more human interest storytelling.
Scott Krzywonos: credits the whole team and John's years of genuine win-win relationship building with industry.
Key Takeaways
The retina acquisition wave is not over. Kodiak and others remain attractive targets as the pipeline continues to mature.
Remigromig's PDR signal is permissive, not causative. Cross-trial data suggest remigromig patients fare better than natural history controls.
Year one of RetinUp: 4,786+ downloads, a year of breaking news, and a field that produced more clinical data in twelve months than most specialties see in a decade.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube
Imvionix has acquired the US and Canadian commercial rights to Beovu from Novartis in its first deal, led by Rick Eiswirth, former CEO of Alimera Sciences. John Kitchens, MD, and Scott Krzywonos react to it, explain why Beovu still matters to some patients, ask what a dedicated owner could change, and name other neglected retina products that could be next.
Hosts: John Kitchens, MD, Scott Krzywonos
Topics Covered
The Deal
Imvionix announced it has acquired exclusive commercial rights to Beovu in the US and Canada from Novartis. Scott reads the press release language about an organization with deep relationships in the retina community being best positioned to “expand the reach of such therapies,” and takes the plural as a sign that more acquisitions may follow.
John knows Rick Eiswirth, who has spent about 20 years in the retina space, and likes the leadership. His hope is that Imvionix helps maintain access to niche products that major manufacturers no longer want to support, as Novartis selling Beovu suggests.
Why Access Matters
Beovu is rarely used in the US, largely because of the retinal vasculitis reports that followed its launch. John still values having it available, because it works for some patients. Scott points to Harrow’s acquisition of Triesence from Alcon as a model: the product was unavailable for a couple of years and is now easy to get.
The Molecule
Brolucizumab was the first second-generation anti-VEGF agent, alongside Vabysmo and Eylea HD. John says the HAWK and HARRIER studies showed a strong drying effect and durability, and that many retina specialists consider it the strongest drying agent.
Scott noticed at this year’s ASRS Preferences and Trends survey posters that Beovu use registered in Asia-Pacific for exudative disease but not in other regions. John, after talks in Australia and Taiwan about six months ago, says physicians there still rely on it for difficult idiopathic polypoidal choroidal vasculopathy. He adds, anecdotally, that they report less retinal vasculitis than first described. Scott wonders whether closer monitoring has reduced the consequences of those events.
What Imvionix Could Do
John calls Beovu an unsupported drug in the US, with no sales force behind it. Scott suggests the label “unsupported” over “orphan,” since orphan implies an orphan indication. He expects support for access and samples, and further research on the inflammatory events. Scott adds patient selection as a likely topic. John doubts that will be enough to raise US share now that faricimab and aflibercept 8 mg are available, but welcomes a company with an identifiable face behind the drug.
Next Candidates
John’s list of neglected products: photodynamic therapy, Retisert (a surgical implant that treats uveitis), and products that keep going on back order, including ICG and fluorescein.
Key Takeaways
Imvionix is built around retina relationships, and the hosts read its press release as a sign of more deals.
Beovu is used sparingly in the US but still helps some patients, especially in Asia-Pacific for polypoidal disease.
A company with a real commercial team behind Beovu could mean access, samples, and new data on inflammation and patient selection.
Products that are niche, withdrawn, or repeatedly back ordered are the next likely acquisition targets.
Credits
Production & Marketing: Laura Brown | Business Operations: Liz Hogan
🎧 Listen at RetinUp.com | Apple Podcasts | Spotify | YouTube